01/02/13 - 07:00 AM EST
Nate Sadeghi breaks down next week's J.P. Morgan Healthcare Conference.
12/17/12 - 07:00 AM EST
Gilead is a great company and stock, but expectations are high and outperformance in 2013 will be tough.
12/17/12 - 06:30 AM EST
The tragedy in Newtown should bring gun owners and opponents together.
12/10/12 - 09:00 AM EST
Eteplirsen is a blockbuster drug for DMD, a view bolstered by Friday's 62-week data.
12/03/12 - 07:00 AM EST
Medical innovation is increasing but ever-escalating drug prices aren't sustainable.
11/26/12 - 07:00 AM EST
TheStreet columnist takes a look back at his best and worst biotech stock calls in 2012.
11/12/12 - 07:00 AM EST
Sales of the cancer drug Adcetris have fallen short but Seattle Genetics' stock price climbs higher.
11/05/12 - 07:00 AM EST
A marginal effective weight-loss pill sold into an overhyped market by a mediocre partner makes Arena a short.
10/31/12 - 08:16 AM EDT
The winnowing of competing hepatitis C drugs has made Achillion's pipeline more compelling.
10/22/12 - 07:00 AM EDT
An FDA decision expected this week could easily go against United Therapeutics.